Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retapamulin Ointment for Secondarily-Infected Traumatic Lesions
NCT00684177Phase 3
Key facts
- Status
- Completed
- Start
- May 2008
- Primary completion
- Oct 2009
- Countries
- 5
- Sponsor
- GSK
- Modality
- Small Molecules
- Drugs
- retapamulin
- Conditions
- traumatic lesion
01
Overview
Phase 3, randomised, double-blind trial in traumatic lesion comparing Retapamulin Ointment, 1% with Placebo Ointment (2 arms). Primary endpoint: Clinical Success and Failure at Follow-up. Started May 2008; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Retapamulin Ointment, 1%
Topical retapamulin ointment applied twice daily for 5 days.
Placebo Ointment
Placebo ointment applied twice daily for 5 days.
03
Who it enrols
Patients aged 2 months or older with secondarily-infected traumatic lesions (laceration, sutured wound, or abrasion) and a specific infection severity score.
04
Endpoints
Primary
Clinical Success and Failure at Follow-up
Secondary
Clinical Success and Failure at Follow-up (ITTB Subset)
Microbiological Success and Failure at Follow-up
Clinical Outcome at End of Therapy
Microbiological Outcome at End of Therapy
Therapeutic Success and Failure at Follow-up
05
Results
Not all primary endpoints met
Beyond the preview
Go deeper on NCT00684177.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00684177.